Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 221-346-0 | CAS number: 3072-84-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 18/01/2012-23/07/2012
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 012
- Report date:
- 2012
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Test material form:
- liquid: viscous
- Details on test material:
- - Name of test material (as cited in study report): Brominated epoxy having epoxy equivalent of 400gr/eq.
- Physical state: pale yellow solid
- Analytical purity: 395.6 gr/eq epoqy equivalent
- Lot/batch No.: B21E-86
- Expiration date of the lot/batch: 30 May 2014
- Storage condition of test material: room temperature in the ark
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Laboratories U.K. Ltd., Oxon, UK.
- Age at study initiation: 6-8 weeks
- Weight at study initiation: males: 218-249g, females: 168-196g
- Fasting period before study: no
- Housing: in solid floor polypropylene cages with stainless steel mesh lids and softwood flake bedding (Datesand Ltd., Cheshire, UK).
- Diet (e.g. ad libitum):ad libitum
- Water (e.g. ad libitum):ad libitum
- Acclimation period:for seven days during which time their health status was assessed.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21 +/- 2°C
- Humidity (%): 55 +/- 15°C
- Air changes (per hr): at least fifteen air changes per hour
- Photoperiod (hrs dark / hrs light): the low intensity fluorescent lighting was controlled to give twelve hours continuous light and twelve hours darkness
IN-LIFE DATES: death after 29 or 43 days
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- arachis oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
DIET PREPARATION
- Rate of preparation of diet (frequency): twice during the study. The formulations were stable for at least twenty one days.
- Storage temperature of food: 4°C
VEHICLE
- Concentration in vehicle: 7.5, 75, 250 mg/ml
- Amount of vehicle (if gavage): 4ml/kg - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The concentration of Brominated Epoxy having Epoxy Equivalent of 400gr/eq in the test item formulations was determined by high performance liquid chromatography (HPLC) using an external standard technique. The test item formulations were extracted with acetonitrile to give a final, theoretical test item concentration of approximately 0.1 mg/ml. Standard solutions of test item were prepared in acetonitrile at a nominal concentration of 0.1 mg/ml.
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- Daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 30 mg/kg bw/day (nominal)
- Dose / conc.:
- 300 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: The dose levels were chosen based on the results of previous toxicity work (Harlan Laboratories Ltd., Project Number 41104821
- Post-exposure recovery period in satellite groups: Recovery group animals were maintained for a further fourteen days treatment-free period following termination of treatment. - Positive control:
- no
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: prior to the start of the treatment and on days 7, 14, 21, 26
- Cage side observations checked in table [2,3,4] were included.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: immediately before dosing, up to thirty minutes post dosing and one and five hours after dosing during the working week. Animals were observed immediately before and after dosing and one hour after dosing at weekends. During the treatment-free period, animals were observed daily.
BODY WEIGHT: Yes
- Time schedule for examinations:immediately before dosing, up to thirty minutes post dosing and one and five hours after dosing during the working week. Animals were observed immediately before and after dosing and one hour after dosing at weekends. During the treatment-free period, animals were observed daily.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No data
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Yes
- Time schedule for examinations: daily
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood:at the end of the treatment period (Day 28) and on all recovery group animals at the end of the treatment-free period (Day 42)
- Anaesthetic used for blood collection: No
- Animals fasted:No
- How many animals: all
- Parameters checked in Addendum 2 were examined. (Haemoglobin, Erythrocyte count, Haematocrit, Erythrocyte indices, Total Leucocyte count, Platelet count, Reticulocyte count, Prothrombin time, Activated partial thromboplastin time)
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: at the end of the treatment period (Day 28) and on all recovery group animals at the end of the treatment-free period (Day 42)
- Animals fasted: No
- How many animals: all
- Parameters examined: urea, glucose, total protein, albumin, albumin/globulin ration, sodium, potaasium, chloride, calcium, inorganic phosphorus, gamma glutamyltranspeptidase, aspartate aminotransferase, alkaline phosphatase, creatinine, triglycerides, total cholesterol, total bilirubin, bile acids.
URINALYSIS: Yes
- Time schedule for collection of urine: week 4 (non-recovery test and control group) and week 6 (all recovery group animals)
- Metabolism cages used for collection of urine: Yes
- Animals fasted: Yes
- Parameters examined: volume, specific gravity, pH, protein, glucose, ketones, bilirubin, urobilinogen, blood
NEUROBEHAVIOURAL EXAMINATION: yes
- Time schedule for examinations:Prior to the start of treatment and on Days 7, 14, 21 and 26, all animals were observed for signs of functional/behavioural toxicity.
- Dose groups that were examined:all
- Battery of functions tested: sensory activity / grip strength / motor activity - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (see table 14, 15)
HISTOPATHOLOGY: Yes (see Appendix 18) - Statistics:
- Where considered appropriate, quantitative data was subjected to statistical analysis to detect the significance of intergroup differences from control; statistical significance was achieved at a level of p<0.05. Statistical analysis was performed on the following parameters:
Grip Strength, Motor Activity, Body Weight Change, Haematology, Blood Chemistry, Urinalysis (Volume and Specific Gravity), Absolute Organ Weights, Body Weight-Relative Organ Weights
Data were analysed using the decision tree from the ProvantisTM Tables and Statistics Module as detailed below:
Where appropriate, data transformations were performed using the most suitable method. The homogeneity of variance from mean values was analysed using Bartlett’s test. Intergroup variance was assessed using suitable ANOVA, or if required, ANCOVA with appropriate covariates. Any transformed data were analysed to find the lowest treatment level that showed a significant effect, using the Williams Test for parametric data or the Shirley Test for non-parametric data. If no dose response was found, but the data shows non-homogeneity of means, the data were analysed by a stepwise Dunnett’s (parametric) or Steel (non-parametric) test to determine significant difference from the control group. Where the data were unsuitable for these analyses, pair-wise tests were performed using the Student t-test (parametric) or the Mann-Whitney U test (non-parametric).
Probability values (p) are presented as follows:
p<0.01 **
p<0.05 *
p≥0.05 (not significant)
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- A reduction in body weight gains was evident for males treated with 1000 mg/kg bw/day when compared to controls, during the treatment period. Statistical significance was achieved for these males during Weeks 1, 3 and 4.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- .
- Food efficiency:
- effects observed, treatment-related
- Description (incidence and severity):
- Food efficiency was reduced for males treated with 1000 mg/kg bw/day.
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Increase in alanine aminotransferase levels. Bile acids were also elevated. Increase in aspartate aminotransferase.
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Higher liver weight of males treated with 1000 mg/kg bw/day
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Minimal centrilobular hypertrophy was evident in all males treated with 1000 and 300 mg/kg bw/day and in three females each treated with 1000 and 300 mg/kg bw/day
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- Clinical signs: no toxicologically significant clinical signs detected in treated animals
Mortality: there were no unscheduled deaths during the study
Body weight: A reduction in body weight gains was evident for males treated with 1000 mg/kg bw/day when compared to controls, during the treatment period. Statistical significance was achieved for these males during Weeks 1, 3 and 4.
No such effects were detected in females treated with 1000 mg/kg bw/day or animals of either sex treated with 300 or 30 mg/kg bw/day.
Food consumption: No adverse effect on food consumption was detected. Food efficiency was however reduced for males treated with 1000 mg/kg bw/day.
Water consumption and compound intake: No toxicologically significant effect on water consumption was detected.
Haematology:There were no toxicologically significant effects detected in the haematological parameters examined.
Clinical chemistry: Animals of either sex treated with 1000 and 300 mg/kg bw/day showed a statistically significant increase in alanine aminotransferase levels (P<0.05 males, P<0.01 females) when compared to controls. Bile acids were also elevated (P<0.01) for animals of either sex treated with 1000 mg/kg bw/day when compared to controls, with the effect extending into the 300 mg/kg bw/day female dose group. Females treated with 1000 and 300 mg/kg bw/day showed an increase in aspartate aminotransferase (P<0.05). Although the changes in these parameters did not demonstrate a true dose related response a number of the individual values were outside the normal expected ranges. Recovery 1000 mg/kg bw/day males continued to show a statistically significant increase in alanine aminotransferase and recovery 1000 mg/kg bw/day females continued to show a statistically significant increase in bile acid following fourteen days without treatment.
No such effects were detected in animals of either sex treated with 30 mg/kg bw/day.
Urinalysis: There were no toxicologically significant effects detected in the urinalytical parameters measured.
Gross pathology: There were no toxicologically significant effects detected in the urinalytical parameters measured.
Organ weights: Males treated with 1000 mg/kg bw/day showed a statistically significant increase (P<0.05) in relative liver weight. The mean relative liver weight was 3% greater than the mean control value. A statistically significant reduction in absolute weight (P<0.05) was however also evident. The effect on liver weight extended to males treated with 300 mg/kg bw/day (P<0.05).
No such effects were detected in females treated with 1000 or 300 mg/kg bw/day or in animals of either sex treated with 30 mg/kg bw/day.
Histopathology: Males treated with 1000 mg/kg bw/day showed a statistically significant increase (P<0.05) in relative liver weight. The mean relative liver weight was 3% greater than the mean control value. A statistically significant reduction in absolute weight (P<0.05) was however also evident. The effect on liver weight extended to males treated with 300 mg/kg bw/day (P<0.05).
No such effects were detected in females treated with 1000 or 300 mg/kg bw/day or in animals of either sex treated with 30 mg/kg bw/day.
Effect levels
open allclose all
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: No observed effects at highest dose tested.
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 300 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- body weight and weight gain
- clinical biochemistry
- food efficiency
- histopathology: non-neoplastic
- organ weights and organ / body weight ratios
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
See study report
Applicant's summary and conclusion
- Conclusions:
- The oral administration of Brominated Epoxy having Epoxy Equivalent of 400gr/eq to rats by gavage, at dose levels of 30, 300 and 1000 mg/kg bw/day, resulted in treatment-related effects in animals of either sex treated with 1000 and 300 mg/kg bw/day.
The effect on body weight gain detected in 1000 mg/kg bw/day males was considered to represent an adverse effect of treatment. The microscopic liver changes (identified as centrilobular hypertrophy) and metabolic blood chemical changes (identified as increases in alanine aminotransferase, aspartate aminotransferase or bile acids) at 1000 and 300 mg/kg bw/day however were a consequence of treatment, but were considered not to represent an adverse health effect. As such the No Observed Adverse Effect Level (NOAEL) was considered to be 1000 mg/kg bw/day for females and 300 mg/kg bw/day for males. - Executive summary:
Introduction: The study was designed to investigate the systemic toxicity of the test item.
Methods: The test item was administered by gavage to three groups, each of five male and five female Wistar Han™:RccHan™:WIST strain rats, for twenty-eight consecutive days, at dose levels of 30, 300 and 1000 mg/kg bw/day. A control group of five males and five females was dosed with vehicle alone (Arachis oil BP). Two recovery groups, each of five males and five females, were treated with the high dose (1000 mg/kg bw/day) or the vehicle alone for twenty-eight consecutive days and then maintained without treatment for a further fourteen days.
Clinical signs, body weight change and food and water consumption were monitored during the study. Haematology, blood chemistry and urinalysis were evaluated for all non-recovery group animals at the end of the treatment period and for all recovery group animals at the end of the treatment-free period.
Results:
Mortality. There were no unscheduled deaths during the study.
Clinical Observations. There were no toxicologically significant clinical signs detected in treated animals.
Behavioural Assessment. There were no toxicologically significant changes in the behavioural parameters measured.
Functional Performance Tests. There were no toxicologically significant changes in functional performance.
Sensory Reactivity Assessments. There were no treatment-related changes in sensory reactivity.
Body Weight. A reduction in body weight gains was evident for males treated with 1000 mg/kg bw/day when compared to controls, during the treatment period. No such effects were detected in females treated with 1000 mg/kg bw/day or animals of either sex treated with 300 or 30 mg/kg bw/day.
Food Consumption. No adverse effect on food consumption was detected. Food efficiency was however reduced for males treated with 1000 mg/kg bw/day.
Water Consumption. There were no toxicologically significant effects on water consumption.
Haematology. There were no toxicologically significant effects detected in the haematological parameters examined.
Blood Chemistry. Animals of either sex treated with 1000 and 300 mg/kg bw/day showed an increase in alanine aminotransferase levels. Bile acids were also higher for animals of either sex treated with 1000 mg/kg bw/day with the effect extending into the 300 mg/kg bw/day female dose group. Females treated with 1000 and 300 mg/kg bw/day showed an increase in aspartate aminotransferase. Recovery 1000 mg/kg bw/day males continued to show an increase in alanine aminotransferase and recovery 1000 mg/kg bw/day females continued to show an increase in bile acid. No such effects were detected in animals of either sex treated with 30 mg/kg bw/day.
Urinalysis: There were no toxicologically significant effects detected in the urinalytical parameters measured.
Necropsy. There were no toxicologically significant macroscopic abnormalities detected.
Organ Weights. Males treated with 1000 and 300 mg/kg bw/day showed a reduction in absolute liver weight. Relative liver weights for these animals were however increased. No such effects were detected for females treated with 1000 or 300 mg/kg bw/day or in animals of either sex treated with 30 mg/kg bw/day.
Histopathology. The following treatment-related microscopic findings were detected:
Liver: Minimal centrilobular hypertrophy was evident in all males treated with 1000 and 300 mg/kg bw/day and in three females each treated with 1000 and 300 mg/kg bw/day. At 1000 mg/kg bw/day, associated minimal increased glycogen deposits was also evident in either sex.
Conclusion. The oral administration of Brominated Epoxy having Epoxy Equivalent of 400gr/eq to rats by gavage, at dose levels of 30, 300 and 1000 mg/kg bw/day, resulted in treatment-related effects in animals of either sex treated with 1000 and 300 mg/kg bw/day.
The effect on body weight gain detected in 1000 mg/kg bw/day males was considered to represent an adverse effect of treatment. The microscopic liver changes (identified as centrilobular hypertrophy) and metabolic blood chemical changes (identified as increases
in alanine aminotransferase, aspartate aminotransferase or bile acids) at 1000 and 300 mg/kg bw/day however were a consequence of treatment, but were considered not to represent an adverse health effect. As such the No Observed Adverse Effect Level (NOAEL) was considered to be 1000 mg/kg bw/day for females and 300 mg/kg bw/day for males.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)
Vaikka kemikaalivirasto tarjoaa paljon verkkoaineistoa kielelläsi, tämä sivu on osittain englanniksi. Lisätietoa viraston monikielisyydestä.
Tervetuloa kemikaaliviraston verkkosivustolle. Internet Explorer 7 (ja aiemmat versiot) ei täysin tue tätä sivustoa. Päivitä Internet Explorerin uudempi versio.
Tällä verkkosivustolla käytetään evästeitä parhaan mahdollisen käyttäjäkokemuksen varmistamiseksi.
Lue lisää evästeiden käytöstä.